The Spectrum of Kidney Involvement in Lymphoma: A Case Report and Review of the LiteratureCOHEN, Lisa J; RENNKE, Helmut G; LAUBACH, Jacob P et al.American journal of kidney diseases. 2010, Vol 56, Num 6, pp 1191-1196, issn 0272-6386, 6 p.Article

Having a Heavy Heart: Approaches to Infiltrative CardiomyopathyLAWLER, Patrick R; BERGMARK, Brian A; LAUBACH, Jacob P et al.Circulation (New York, N.Y.). 2014, Vol 129, Num 16, pp 1703-1711, issn 0009-7322, 9 p.Article

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomideYEE, Andrew J; HARI, Parameswaran; GHOBRIAL, Irene M et al.British journal of haematology. 2014, Vol 166, Num 3, pp 401-409, issn 0007-1048, 9 p.Article

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancersRICHARDSON, Paul G; MITSIADES, Constantine S; LAUBACH, Jacob P et al.British journal of haematology. 2011, Vol 152, Num 4, pp 367-379, issn 0007-1048, 13 p.Article

Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate TherapyPATEL, Chirayu G; YEE, Andrew J; ANDERSON, Kenneth C et al.Clinical cancer research (Print). 2014, Vol 20, Num 15, pp 3955-3961, issn 1078-0432, 7 p.Article

Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignanciesRICKLES, Richard J; PIERCE, Laura T; GIORDANO, Thomas P et al.Blood. 2010, Vol 116, Num 4, pp 593-602, issn 0006-4971, 10 p.Article

Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and BortezomibMITSIADES, Constantine S; HIDESHIMA, Teru; CHAUHAN, Dharminder et al.Seminars in hematology. 2009, Vol 46, Num 2, pp 166-175, issn 0037-1963, 10 p.Article

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trialJAKUBOWIAK, Andrzej J; GRIFFITH, Kent A; ANDERSON, Tara et al.Blood. 2011, Vol 118, Num 3, pp 535-543, issn 0006-4971, 9 p.Article

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myelomaGHOBRIAL, Irene M; MUNSHI, Nikhil C; WOOLDRIDGE, James E et al.American journal of hematology. 2011, Vol 86, Num 7, pp 573-578, issn 0361-8609, 6 p.Article

Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in MyelomaMITSIADES, Constantine S; DAVIES, Faith E; LAUBACH, Jacob P et al.Journal of clinical oncology. 2011, Vol 29, Num 14, pp 1916-1923, issn 0732-183X, 8 p.Article